About Tandem Diabetes Care, Inc. 
Tandem Diabetes Care, Inc.
Pharmaceuticals & Biotechnology
Tandem Diabetes Care, Inc. is a medical device company engaged in the designing, developing and commercialization of products for people with insulin-dependent diabetes. The Company’s manufacturing, sales and support activities principally focus on its flagship pump platform, the t:slim X2 Insulin Delivery System (t:slim X2), and its product offerings. The t:slim X2 is based on its technology platform and is capable of remote feature updates and is designed to display continuous glucose monitoring (CGM) sensor information directly on the pump home screen. Its products also include Basal-IQ technology and Control-IQ technology. The Basal-IQ technology is a predictive low glucose suspend feature that is designed to temporarily suspend insulin delivery to help reduce the frequency and duration of hypoglycemic events. The Control-IQ technology is a hybrid-closed loop feature, designed to help increase a user's time in targeted glycemic range.
Company Coordinates 
Company Details
11075 Roselle St , SAN DIEGO CA : 92121-1204
Registrar Details
Shareholding Snapshot
Shareholding Compare (%holding) 
Majority shareholders
Domestic Funds
Domestic Funds
Held in 87 Schemes (59.77%)
Foreign Institutions
Held by 152 Foreign Institutions (16.83%)
Strategic Entities with highest holding
Highest Public shareholder
Management
Designation
Mr. Kim Blickenstaff
Chairman of the Board
Mr. John Sheridan
President, Chief Executive Officer, Director
Mr. Dick Allen
Lead Independent Director
Mr. Rajwant Sodhi
Director
Mr. Edward Cahill
Independent Director
Ms. Peyton Howell
Independent Director
Kathleen McGroddy-Goetz
Independent Director
Revenue and Profits:
Net Sales:
241 Million
(Quarterly Results - Jun 2025)
Net Profit:
-52 Million
Pharmaceuticals & Biotechnology
USD 845 Million (Small Cap)
NA (Loss Making)
NA
0.00%
0.10
-82.74%
6.34






